Immune Checkpoint Modulation in Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) represents the majority of lung malignancies and has historically carried a poor prognosis under conventional therapies. The advent of immune checkpoint modulation has redefined treatment paradigms by harnessing endogenous T-cell responses against tumour cells. Key targets include the programmed death-1 (PD-1) receptor and its ligand PD-L1, as well as cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), each of which acts to restrain T-cell activation in physiological contexts. In NSCLC, tumour cells exploit these pathways to evade immunosurveillance. Blockade of these inhibitory axes has led to durable responses in subsets of patients, yet primary and acquired resistance, heterogeneous biomarker expression and immune-related adverse events remain challenges. Contemporary research thus focuses on combination strategies, novel biomarkers for response prediction and mechanisms of resistance within the tumour microenvironment. Advances in bispecific antibodies, rational pairing with chemotherapy or radiotherapy, and deeper understanding of immune cell phenotypes are setting the stage for personalised immunotherapy in NSCLC.

Research from Nature Portfolio

A seminal review has synthesised a decade of clinical and mechanistic insights into immune-checkpoint inhibitors across tumour types, highlighting how lessons from early trials have informed current dosing strategies, toxicity management and the development of next-generation modulators. This work emphasises the dynamic interplay between tumour genetics, host immunity and checkpoint blockade, underscoring the need for integrated biomarker panels rather than single-parameter assays. Complementing this, another study elucidated how tobacco carcinogens activate the aryl hydrocarbon receptor in lung epithelium to upregulate PD-L1, promoting immune escape. High receptor expression correlated with improved outcomes under anti-PD-1 therapy and experimental inhibition of this axis enhanced efficacy in murine models, suggesting a novel target for combination treatment in smoking-related NSCLC.

Immune Checkpoint Modulation in Non-Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in immune checkpoint modulation in non-small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Immune checkpoint: A regulatory pathway that maintains self-tolerance by down-modulating T-cell activation.

Programmed death-1 (PD-1): An inhibitory receptor on T cells that limits immune responses upon binding its ligands.

Programmed death-ligand 1 (PD-L1): A surface protein often upregulated on tumour cells to suppress cytotoxic T-cell function.

Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4): A receptor that competes with costimulatory signals to inhibit early T-cell activation.

Tumour microenvironment (TME): The complex milieu of cancer cells, immune infiltrates and stromal elements surrounding a tumour.

References

1. A decade of immune-checkpoint inhibitors in cancer therapy. Nature Communications (2020).
2. The Aryl hydrocarbon receptor mediates tobacco-induced PD-L1 expression and is associated with response to immunotherapy. Nature Communications (2019).
3. Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer. Journal of Hematology & Oncology (2024).
4. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell (2024).
5. Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology (2024).